Nina Martino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nina Martino has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Pablo Adam
Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York, U.S.A.
4 shared publications Ramon Bossardi Ramos
Department of Molecular and Cellular Physiology, Albany Medical College, United States
2 shared publications- Shuhan Lu
Hastings Center for Pulmonary Research, Keck School of Medicine, University of Southern California, Los Angeles, USA
2 shared publications Abigail E Salinero
Department of Neuroscience & Experimental Therapeutics, Albany Medical College, United States
1 shared publication- Alexander A. Mongin
Department of Neuroscience and Experimental Therapeutics, Albany Medical College
1 shared publication - Alexandra R. Paul
Department of Neurosurgery, Albany Medical Center, Albany, New York, USA
1 shared publication
Latest Publications
- 4 February 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (5) , 1995-2026
LRRC8A‐containing anion channels promote glioblastoma proliferation via a WNK1/mTORC2‐dependent mechanism
Leucine‐rich repeat‐containing protein 8A (LRRC8A) is an essential subunit of the ubiquitously expressed volume‐regulated anion channels (VRACs). Previous work has shown that LRRC8A is overexpressed in several cancers and is associated with poor survival outcomes. However, the underlying mechanisms remain obscure. In the present study, we investigated the role of LRRC8A and VRACs in the progression of glioblastoma (GBM), the most common and aggressive primary brain tumour. We found that, compared with healthy brain tissue, LRRC8A mRNA is significantly upregulated in surgical GBM specimens, patient‐derived GBM cell lines and GBM datasets from The Cancer Genome Atlas. GBM patients in the lowest quartile of LRRC8A expression exhibited a trend toward longer survival. In patient‐derived GBM cultures, RNA interference‐mediated knockdown of LRRC8A or pharmacological blockade of VRAC with 4,4′‐diisothiocyano‐2,2′‐stilbenedisulfonic acid (DIDS) reduced cell proliferation, lowered intracellular chloride levels and inhibited activity of mammalian target of rapamycin (mTOR) complex 2 (mTORC2). The anti‐proliferative effects of LRRC8A knockdown and DIDS were non‐additive, suggesting a shared mechanism. Biochemical and molecular analyses revealed that LRRC8A‐containing VRACs promote GBM cell proliferation through a new non‐enzymatic function of the chloride‐sensitive protein kinase WNK1. Specifically, VRAC activity facilitates WNK1‐dependent activation of mTORC2 and its downstream kinases AKT and SGK. In support of this model, either downregulation of WNK1 or pharmacological inhibition of mTOR or SGK/AKT suppressed GBM cell proliferation and mimicked the effect of LRRC8A knockdown. Together, these findings establish a new mTORC2‐centric signalling axis for VRAC‐dependent control of cellular functions and highlight several potential molecular targets for limiting GBM proliferation. image Key points: Volume‐regulated anion channels (VRACs) are considered to contribute to the progression of several human cancers. The essential VRAC subunit LRRC8A is significantly overexpressed in clinical specimens of glioblastoma, the most common and aggressive primary brain malignancy. RNA interference‐mediated downregulation of LRRC8A reduces proliferation in patient‐derived GBM cell cultures, suggesting that VRACs promote cancer cell growth. LRRC8A/VRAC‐mediated effects on cell proliferation are driven by a mechanism involving the chloride‐sensitive protein kinase WNK1, mTOR complex 2 and activation of downstream kinases AKT and SGK.
- 4 February 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (5) , 1995-2026
LRRC8A‐containing anion channels promote glioblastoma proliferation via a WNK1/mTORC2‐dependent mechanism
Leucine‐rich repeat‐containing protein 8A (LRRC8A) is an essential subunit of the ubiquitously expressed volume‐regulated anion channels (VRACs). Previous work has shown that LRRC8A is overexpressed in several cancers and is associated with poor survival outcomes. However, the underlying mechanisms remain obscure. In the present study, we investigated the role of LRRC8A and VRACs in the progression of glioblastoma (GBM), the most common and aggressive primary brain tumour. We found that, compared with healthy brain tissue, LRRC8A mRNA is significantly upregulated in surgical GBM specimens, patient‐derived GBM cell lines and GBM datasets from The Cancer Genome Atlas. GBM patients in the lowest quartile of LRRC8A expression exhibited a trend toward longer survival. In patient‐derived GBM cultures, RNA interference‐mediated knockdown of LRRC8A or pharmacological blockade of VRAC with 4,4′‐diisothiocyano‐2,2′‐stilbenedisulfonic acid (DIDS) reduced cell proliferation, lowered intracellular chloride levels and inhibited activity of mammalian target of rapamycin (mTOR) complex 2 (mTORC2). The anti‐proliferative effects of LRRC8A knockdown and DIDS were non‐additive, suggesting a shared mechanism. Biochemical and molecular analyses revealed that LRRC8A‐containing VRACs promote GBM cell proliferation through a new non‐enzymatic function of the chloride‐sensitive protein kinase WNK1. Specifically, VRAC activity facilitates WNK1‐dependent activation of mTORC2 and its downstream kinases AKT and SGK. In support of this model, either downregulation of WNK1 or pharmacological inhibition of mTOR or SGK/AKT suppressed GBM cell proliferation and mimicked the effect of LRRC8A knockdown. Together, these findings establish a new mTORC2‐centric signalling axis for VRAC‐dependent control of cellular functions and highlight several potential molecular targets for limiting GBM proliferation. image Key points: Volume‐regulated anion channels (VRACs) are considered to contribute to the progression of several human cancers. The essential VRAC subunit LRRC8A is significantly overexpressed in clinical specimens of glioblastoma, the most common and aggressive primary brain malignancy. RNA interference‐mediated downregulation of LRRC8A reduces proliferation in patient‐derived GBM cell cultures, suggesting that VRACs promote cancer cell growth. LRRC8A/VRAC‐mediated effects on cell proliferation are driven by a mechanism involving the chloride‐sensitive protein kinase WNK1, mTOR complex 2 and activation of downstream kinases AKT and SGK.
- 26 July 2024
- Published by Elsevier in Neuroscience
- Vol. 555, 194-204
A transient brain endothelial translatome response to endotoxin is associated with mild cognitive changes post-shock in young mice
- 26 July 2024
- Published by Elsevier in Neuroscience
- Vol. 555, 194-204
A transient brain endothelial translatome response to endotoxin is associated with mild cognitive changes post-shock in young mice
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 323 (2) , C556-C569
SOCS3 limits TNF and endotoxin-induced endothelial dysfunction by blocking a required autocrine interleukin-6 signal in human endothelial cells
Increased circulating levels of soluble interleukin (IL)-6 receptor α (sIL-6Rα) are commonly observed during inflammatory responses, allowing for IL-6 signaling in cells that express the ubiquitous receptor subunit gp130 but not IL-6Rα, such as endothelial cells. Activation of Toll-like receptor (TLR)-4 or the tumor necrosis factor (TNF) receptor leads to NF-κB-dependent increases in endothelial IL-6 expression. Thus, we hypothesize that danger signals may induce autocrine IL-6 signaling within the endothelium via sIL-6Rα-mediated trans-signaling. In support of this hypothesis, we recently demonstrated that conditional deletion in the endothelium of the IL-6 signaling inhibitor SOCS3 leads to rapid mortality in mice challenged with the TLR-4 agonist endotoxin through increases in vascular leakage, thrombosis, leukocyte adhesion, and a type I-like interferon response. Here, we sought to directly test a role for sIL-6Rα in LPS-treated human umbilical vein and dermal blood microvascular endothelial cells. We show that cotreatment with sIL-6Rα dramatically increases the loss of barrier function and the expression of COX2 and tissue factor mRNA levels induced by LPS. This cotreatment led to strong activation of STAT1 and STAT3 while not affecting LPS-induced activation of p38 and NF-κB signaling. Similar results were obtained when sIL-6Rα was added to a TNF challenge. JAK inhibition by pretreatment with ruxolitinib or by SOCS3 overexpression blunted LPS and sIL-6R synergistic effects, whereas SOCS3 knockdown further increased the response. Together, these findings demonstrate that IL-6 signaling downstream of NF-κB activation leads to a strong endothelial activation and may explain the acute endotheliopathy observed during critical illness.
- 1 August 2022
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 323 (2) , C556-C569
SOCS3 limits TNF and endotoxin-induced endothelial dysfunction by blocking a required autocrine interleukin-6 signal in human endothelial cells
Increased circulating levels of soluble interleukin (IL)-6 receptor α (sIL-6Rα) are commonly observed during inflammatory responses, allowing for IL-6 signaling in cells that express the ubiquitous receptor subunit gp130 but not IL-6Rα, such as endothelial cells. Activation of Toll-like receptor (TLR)-4 or the tumor necrosis factor (TNF) receptor leads to NF-κB-dependent increases in endothelial IL-6 expression. Thus, we hypothesize that danger signals may induce autocrine IL-6 signaling within the endothelium via sIL-6Rα-mediated trans-signaling. In support of this hypothesis, we recently demonstrated that conditional deletion in the endothelium of the IL-6 signaling inhibitor SOCS3 leads to rapid mortality in mice challenged with the TLR-4 agonist endotoxin through increases in vascular leakage, thrombosis, leukocyte adhesion, and a type I-like interferon response. Here, we sought to directly test a role for sIL-6Rα in LPS-treated human umbilical vein and dermal blood microvascular endothelial cells. We show that cotreatment with sIL-6Rα dramatically increases the loss of barrier function and the expression of COX2 and tissue factor mRNA levels induced by LPS. This cotreatment led to strong activation of STAT1 and STAT3 while not affecting LPS-induced activation of p38 and NF-κB signaling. Similar results were obtained when sIL-6Rα was added to a TNF challenge. JAK inhibition by pretreatment with ruxolitinib or by SOCS3 overexpression blunted LPS and sIL-6R synergistic effects, whereas SOCS3 knockdown further increased the response. Together, these findings demonstrate that IL-6 signaling downstream of NF-κB activation leads to a strong endothelial activation and may explain the acute endotheliopathy observed during critical illness.
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Role of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization
Interleukin‐6 (IL‐6) is a major cytokine within the cytokine storm that occurs in response to severe systemic inflammation and sepsis. This cytokine promotes the activation of the JAK/STAT3 pathway. SOCS3, a protein induced by STAT3, acts as the main inhibitor this pathway. Prior work demonstrated that loss of SOCS3 in the endothelium of mice treated with LPS led to fast mortality within 16‐24 hours post‐challenge. The aim of this study is to determine the role of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization in this severe, acute inflammatory model. We generated tamoxifen inducible SOCS3 knockout mice and induced severe acute inflammation by IP injection with LPS. Mice were evaluated for severity after 15 hours and euthanized for tissue collecting 16 hours after LPS injection. We found higher LPS‐induced severity in SOCS3iEKO mice compared to littermate controls. We observed significant weight loss after endotoxin, but surprisingly SOCS3iEKO mice displayed less weight loss, which could be due to fluid accumulation driven by increased systemic edema. Therefore, we interrogated whether SOCS3 loss promoted endothelial permeability. Lung and brain microvascular permeability was assayed by injecting FITC‐labeled 70kDa dextran 30 minutes prior to euthanasia and perfusion with PBS. Consistent with increased leakage, extravasated dextran was detected in thick (50‐100) um sections of LPS treated SOCS3iEKO mice. We hypothesized that this higher permeability could be due to increased leukocyte accumulation. In fact, we detected very high levels P‐selectin mRNA level in the kidneys, livers and lungs of LPS treated SOCS3iEKO mice, suggesting an increased adhesivity to leukocytes of the affected vasculature. To assess this, we stained flat mount retinas for P‐selectin and CD45 (pan‐leukocyte). LPS‐treated SOCS3iEKO mice showed a dramatic accumulation of intravascular leukocytes and increased P‐selectin expression. Intravascular leukocytes were also detected by standard H&E staining of lungs, livers and kidneys of SOCS3iEKO mice. In sum, we found that the lethality observed after a single endotoxin challenge in mice lacking endothelial SOCS3 is associated with increased intraluminal leukocyte adhesion and endothelial permeability.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessRole of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization
Interleukin‐6 (IL‐6) is a major cytokine within the cytokine storm that occurs in response to severe systemic inflammation and sepsis. This cytokine promotes the activation of the JAK/STAT3 pathway. SOCS3, a protein induced by STAT3, acts as the main inhibitor this pathway. Prior work demonstrated that loss of SOCS3 in the endothelium of mice treated with LPS led to fast mortality within 16‐24 hours post‐challenge. The aim of this study is to determine the role of endothelial SOCS3 in brain permeability and retinal vascular leukoembolization in this severe, acute inflammatory model. We generated tamoxifen inducible SOCS3 knockout mice and induced severe acute inflammation by IP injection with LPS. Mice were evaluated for severity after 15 hours and euthanized for tissue collecting 16 hours after LPS injection. We found higher LPS‐induced severity in SOCS3iEKO mice compared to littermate controls. We observed significant weight loss after endotoxin, but surprisingly SOCS3iEKO mice displayed less weight loss, which could be due to fluid accumulation driven by increased systemic edema. Therefore, we interrogated whether SOCS3 loss promoted endothelial permeability. Lung and brain microvascular permeability was assayed by injecting FITC‐labeled 70kDa dextran 30 minutes prior to euthanasia and perfusion with PBS. Consistent with increased leakage, extravasated dextran was detected in thick (50‐100) um sections of LPS treated SOCS3iEKO mice. We hypothesized that this higher permeability could be due to increased leukocyte accumulation. In fact, we detected very high levels P‐selectin mRNA level in the kidneys, livers and lungs of LPS treated SOCS3iEKO mice, suggesting an increased adhesivity to leukocytes of the affected vasculature. To assess this, we stained flat mount retinas for P‐selectin and CD45 (pan‐leukocyte). LPS‐treated SOCS3iEKO mice showed a dramatic accumulation of intravascular leukocytes and increased P‐selectin expression. Intravascular leukocytes were also detected by standard H&E staining of lungs, livers and kidneys of SOCS3iEKO mice. In sum, we found that the lethality observed after a single endotoxin challenge in mice lacking endothelial SOCS3 is associated with increased intraluminal leukocyte adhesion and endothelial permeability.